non-cystic fibrosis bronchiectasis (nCFB), Chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
Drug: BI 1291583
Other: Placebo
Route: oral
Sponsors
Mizuguchi Yuto
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Healthy male subjects, age of 20 to 45 years (inclusive), body mass index (BMI) of 18.5 to 25.0 kg/m2 (inclusive)
Exclusion criteria
Exclusion criteria: Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease assessed as clinically relevant by the investigator Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders Chronic or relevant acute infections (including positive result of either Hepatitis A antibodies, Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B core antibody, Hepatitis C antibodies, HIV antigen and antibody, T-SPOT or Syphilis test at Screening)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the percentage [%] of subjects with drug-related AEs per treatment group | — |
Contacts
Public ContactYuji Takasu
Boehringer Ingelheim
Outcome results
None listed